^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:veliparib (ABT-888) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO-BC-I 2020
    Title:

    140O - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial

    Published date:
    05/24/2020
    Excerpt:
    The addition of Vel to C-P improved PFS in gBRCA pts with HR+ BC and TNBC .
    Secondary therapy:
    carboplatin + paclitaxel
    Trial ID:
    BROCADE3
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

    Excerpt:
    ...- Phase I: Patients must have received at least one prior chemotherapy regimen for metastatic disease; patients with deleterious germ line mutations in breast cancer (BRCA)1 or BRCA2 are...
    Trial ID:
    NCT01351909
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

    Excerpt:
    ...- HER negative with a known germline BRCA1/2 mutation...
    Trial ID:
    NCT01251874